Careers

Actinium Pharmaceuticals, Inc. is focused on developing therapies for the treatment of cancer patients with unmet needs with the goal of improving patients’ outcomes. If you share in this vision and are interested in joining the Actinium team please feel free to submit your resume by email to careers@actiniumpharma.com.

Actinium is currently looking for candidates for the following positions.

Openings

Bone Marrow Transplant Induction and Conditioning in One

Iomab-B, Actinium’s lead asset, is being studied in the pivotal Phase 3 SIERRA clinical trial as an induction and conditioning agent in patients over the age of 55 with active relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. The SIERRA trial completed patient enrollment in the third quarter of 2021. View highlights of Key Opinion Leaders discussing Iomab-B:

View Clinical Panel Discussion

Robust Pipeline

Actinium Pharmaceuticals' drug development pipeline features Iomab-B, which completed enrollment of its pivotal Phase 3 clinical trial, Iomab-ACT, which is intended to be a conditioning regimen for cell and gene therapies that is being studied in an NIH funded clinical study and Actimab-A, which is being studied in two combination trials for relapsed/refractory AML. Actinium is focused on continuing to expand its drug development pipeline of targeted radiotherapies for patients with blood cancers and solid tumors.

View Pipeline

Careers

Openings

Bone Marrow Transplant Induction and Conditioning in One

Robust Pipeline

Email Sign Up